9 results
Primary Objective* To estimate the proportion of subjects who flare within 40 weeks followingwithdrawal of ETN in subjects who have achieved ASDAS CRP less than1.3 (inactive disease).Secondary Objectives* To estimate time to flare after withdrawal…
Our main aim is to evaluate the effectiveness and cost-effectiveness of two tapering strategies:(i)DMARD tapering and (ii)anti-TNF tapering in RA patients with DMARD&anti-TNF(etanercept, adalimumab, certolizumab or golimumab) induced…
Hypothesis: Fiducial markers implanted in mediastinal lymph nodes by EUS-FNA or EBUS will show inter and intra-fraction lymph node position variability on 4D-(CB) CT-scansObjective: To quantify respiratory induced mediastinal lymph node motion and…
To determine the minimal biologic drug serum trough concentration required to maintain stable disease activity in patientswith moderate to severe chronic plaque psoriasis.
We hypothesize that treatment of RA can be individualized by taking into account the presence of autoantibodies and quick response to glucocorticoids and JAK inhibitors. Therefore, the aims of this randomized controlled trial are: 1. To compare…
The primary objective is to evaluate whether a switching strategy using adalimumab concentration (TDM) is superior to usual care in rheumatoid arthritis patients failing adalimumab treatment with regard to response rates. The secondary objectives…
The aim of this feasibility study is to validate pre-treatment [89Zr]-bevacizumab PET/CT as an imaging biomarker for prediction of treatment response to bevacizumab treatment in patients with NF2 related (vestibular) schwannomas.
To study whether polytherapy (methotrexate plus sulfasalazine plus hydroxychloroquine) results in more patients with inactive disease and therefore less patients who need treatment with a TNF inhibitor after 6 months of treatment compared to primary…
Primary objective:Identify pre-treatment profiles with integrated clinical, transcriptomic, metabolomic, proteomic, flow cytometric, and imaging data that predict response to treatment with tofacitinib, in DMARD-naïve and DMARD non-responsive PsA…